Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Prochlorperazine given during your chelation therapy with deferoxamine may have additive adverse effects.
What might happen:
The combination could lead to loss of consciousness (unable to respond to people and activities).
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change your anti-nausea medicine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Smythies J. Does the O'Brien cycle occur in vivo as a key component in H(2)O(2) production and redox signalling?. Med Hypotheses 2011 Feb; 76(2):299-301.
2.Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, Chen TJ, Bai YM. Association between psychiatric disorders and iron deficiency anemia among children and adolescents: a nationwide population-based study. BMC Psychiatry 2013;13:161.
3.Picchietti DL, Wang VC, Picchietti MA. Intravenous iron given prior to pregnancy for restless legs syndrome is associated with remission of symptoms. J Clin Sleep Med 2012 Oct 15;8(5):585-6.
4.Earley CJ. Clinical practice. Restless legs syndrome. N Engl J Med 2003 May 22;348(21):2103-9.
5.Hegde NV, Jensen GL, Unger EL. Iron chelation down-regulates dopamine transporter expression by decreasing mRNA stability and increasing endocytosis in N2a cells. Exp Cell Res 2011 Feb 15;317(4):405-12.
6.Prochlorperazine maleate US prescribing information. Sandoz Inc. September, 2010.
7.Blake DR, Winyard P, Lunec J, Williams A, Good PA, Crewes SJ, Gutteridge JM, Rowley D, Halliwell B, Cornish A, et al. Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 1985 Jul;56(219):345-55.
8.Desferal (deferoxamine mesylate) US prescribing information. Novartis Pharmaceuticals Corporation December, 2011.